Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.076
Neutral
RSI(14)
54.185
Neutral
STOCH(KDJ)(9,3,3)
56.282
Sell
ATR(14)
0.620
Low Volatility
CCI(14)
79.889
Neutral
Williams %R
24.686
Buy
TRIX(12,20)
0.053
Sell
StochRSI(14)
21.077
Sell
Lyell Immunopharma Inc
LYEL11.080USD
-0.020-0.18%
Close 08/29, 16:00（ET）Quotes delayed by 15 min
164.33MMarket Cap
LossP/E TTM
TradingKey Stock Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Peers
TradingKey Stock Score
Currency: USD Updated：2025-08-29Key Insights
The company's fundamentals are relatively stable.Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Hold.Despite an average stock market performance, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
2
analysts
Hold
Current Rating
11.000
Target Price
-0.90%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company advancing a pipeline of product candidates enhanced with its proprietary anti-exhaustion technologies for patients with solid tumors or hematologic malignancies. The Company's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to resist exhaustion and kill cancer cells. Its technologies are designed to generate T cells with the ability to persist and self-renew while driving tumor cytotoxicity. Its two product candidates, LYL797 and LYL845, are in Phase I clinical development, and an additional product candidate, LYL119, is entering Phase I clinical development. The Company is also engaged in accelerating the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma.
Growing
The company is in a growing phase, with the latest annual income totaling USD 61.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 87.31.
Overvalued
The company’s latest PE is -0.34, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 11.42M shares, decreasing 5.16% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 442.63K shares of this stock.
Financial Health
Currency: USD Updated：2025-08-29The company's current financial score is 5.61, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 7.00K, representing a year-over-year increase of 133.33%, while its net profit experienced a year-over-year increase of 13.96%.
Score
Financials
5.75
Related Indicators
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.23
Operational Efficiency
0.82
Growth Potential
7.17
Shareholder Returns
7.07
Valuation Dimension
Currency: USD Updated：2025-08-29The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -0.35, which is 353.27% below the recent high of -1.59 and -746.16% above the recent low of -2.96.
Score
Valuation Dimension
P/E
P/B
P/S
P/CF
Industry Ranking 173/690
No Data
Forecast
Currency: USD Updated：2025-08-29The company’s current earnings forecast score is 5.00, which is lower than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Lyell Immunopharma Inc is 11.00, with a high of 12.00 and a low of 10.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
2
analysts
Hold
Current Rating
11.000
Target Price
-0.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Lyell Immunopharma Inc
LYEL
2
CRISPR Therapeutics AG
CRSP
29
Ionis Pharmaceuticals Inc
IONS
27
Intellia Therapeutics Inc
NTLA
27
Exact Sciences Corp
EXAS
27
IQVIA Holdings Inc
IQV
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Momentum
Currency: USD Updated：2025-08-29The company’s current price momentum score is 9.02, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 12.78 and the support level at 9.53, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
11.078
Buy
MA10
10.917
Buy
MA20
10.933
Buy
MA50
10.428
Buy
MA100
6.728
Buy
MA200
3.711
Buy
Institutional Confidence
Currency: USD Updated：2025-08-29The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 73.88%, representing a quarter-over-quarter decrease of 3.84%. The largest institutional shareholder is The Vanguard, holding a total of 442.63K shares, representing 2.30% of shares outstanding, with 31.07% decrease in holdings.
Score
Institutional Shareholding
No Data
Risk Assessment
Currency: USD Updated：2025-08-29The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.06, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is -0.20. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
-0.20
VaR
--
240-Day Maximum Drawdown
+75.00%
240-Day Volatility
+321.00%
Return
Best Daily Return
60 days
+68.59%
120 days
+1782.30%
5 years
--
Worst Daily Return
60 days
-14.92%
120 days
-14.92%
5 years
--
Sharpe Ratio
60 days
+1.46
120 days
+1.45
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+75.00%
3 years
+94.25%
5 years
--
Return-to-Drawdown Ratio
240 days
+10.68
3 years
+0.25
5 years
--
Skewness
240 days
+15.43
3 years
+26.47
5 years
--
Volatility
Realised Volatility
240 days
+321.00%
5 years
--
Standardised True Range
240 days
+3.30%
5 years
--
Downside Risk-Adjusted Return
120 days
+6772.14%
240 days
+6772.14%
Maximum Daily Upside Volatility
60 days
+73.37%
Maximum Daily Downside Volatility
60 days
+84.51%
Liquidity
Average Turnover Rate
60 days
+0.05%
120 days
+0.15%
5 years
--
Turnover Deviation
20 days
-97.11%
60 days
-86.88%
120 days
-58.62%
Peers
Currency: USD Updated：2025-08-29Lyell Immunopharma Inc
LYEL
5.38 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.64 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Zoetis Inc
ZTS
7.57 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.55 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
7.54 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
7.48 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
